Abstract:BACKGROUND A number of preclinical studies in both in vitro and in vivo models of Parkinson's disease have demonstrated that coenzyme Q10 can protect the nigrostriatal dopaminergic system. Some clinical trials have looked at the neuroprotective effects of coenzyme Q10 in patients with early and midstage Parkinson's disease. OBJECTIVES To assess the evidence from randomized controlled trials on the efficacy and safety of treatment with coenzyme Q10 compared to placebo in patients with early and midstage Parkinson's disease. SEARCH METHODS We searched the Cochrane Movment Disorders Group Trials Register, CENTRAL (The Cochrane Library 2009, Issue 4), MEDLINE (January 1966 to March 2011), and EMBASE (January 1985 to March 2011). We handsearched the references quoted in the identified trials, congress reports from the most important neurological association and movement disorder societies in Europe and America (March 2011), checked reference lists of relevant studies and contacted other researchers. SELECTION CRITERIA We included randomized controlled trials (RCTs) that compared coenzyme Q10 to placebo for patients who suffered early and midstage primary Parkinson's disease. Studies in which the method of randomization or concealment were unknown were included. Cross-over studies were excluded. DATA COLLECTION AND ANALYSIS Two review authors independently assessed trial quality and extracted data. All disagreements were resolved by consensus between authors and were explained. We attempted to contact the authors of studies for further details if any data were missing and to establish the characteristics of unpublished trials through correspondence with the trial coordinator or principal investigator. Adverse effects information was collected from the trials. MAIN RESULTS Four randomized, double-blind, placebo-controlled trials with a total of 452 patients met the inclusion criteria and were included in the review. In overall, there were improvements in activities of daily living (ADL) UPDRS (WMD -3.12, 95% CI -5.88 to -0.36) and Schwab and England (WMD 4.43, 95% CI 0.05 to 8.81) for coenzyme Q10 at 1200 mg/d for 16 months versus placebo.In safety outcomes, only the risk ratios (RR) of pharyngitis (RR 1.04, 95% CI 0.18 to 5.89) and diarrhea (RR 1.39, 95% CI 0.62 to 3.16) are mild elevated between coenzyme Q10 therapy and placebo and there were no differences in the number of withdrawals due to adverse effects (RR 0.61, 95% CI 0.23 to 1.62). AUTHORS' CONCLUSIONS Coenzyme Q10 therapy with 1200 mg/d for 16 months was well tolerated by patients with Parkinson's disease. The improvements in ADL UPDRS and Schwab and England were positive, but it need to be further confirmed by larger sample. For total and other subscores of UPDRS, the effects of coenzyme Q10 seemed to be less clear.

Coenzyme Q10: A Review of Its Promise as a Neuroprotectant

Coenzyme Q10 effects in neurological diseases.

Neuroprotective effects of coenzyme Q10 on neurological diseases: a review article

Coenzyme Q10 a mitochondrial restorer for various brain disorders

Coenzyme Q10, Ageing and the Nervous System: An Overview

Coenzyme Q10 and Dementia: A Systematic Review

Coenzyme Q10: Clinical Applications beyond Cardiovascular Diseases

Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease

Coenzyme Q-10 in Human Health: Supporting Evidence?

Coenzyme Q10 supplementation – In ageing and disease

Water-soluble CoQ10 as A Promising Anti-aging Agent for Neurological Dysfunction in Brain Mitochondria

Coenzyme Q10 Supplementation in Aging and Disease

Clinical aspects of coenzyme Q10: An update

Coenzyme Q10 for Parkinson's Disease

Cellular Consequences of Coenzyme Q10 Deficiency in Neurodegeneration of the Retina and Brain

Coenzyme Q10 protects astrocytes from ROS-induced damage through inhibition of mitochondria-mediated cell death pathway

Therapeutic Effects of Coenzyme Q10 in the Treatment of Ischemic Stroke

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

Coenzyme Q10 Supplementation for the Reduction of Oxidative Stress: Clinical Implications in the Treatment of Chronic Diseases

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases